The present invention provides a compound represented by the formula:
wherein Ar is an aryl group optionally having substituents, R is a C
1-6
alkyl group, R
1
is a hydrogen atom, a hydrocarbon group optionally having substituents, an acyl group or a heterocyclic group optionally having substituents, X is an oxygen atom or an imino group optionally having substituents, ring A is a piperidine ring optionally further having substituents, and ring B is a benzene ring having substituents, or a salt thereof, and an agent for the prophylaxis or treatment of lower urinary tract abnormality and the like, which contains the compound.
[EN] INHIBITORS OF APOL1 AND USE OF THE SAME<br/>[FR] INHIBITEURS D'APOL1 ET LEUR UTILISATION
申请人:VERTEX PHARMA
公开号:WO2021252859A1
公开(公告)日:2021-12-16
The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.
Piperidine derivative crystal, process for producing the same, and use
申请人:Ikeura Yoshinori
公开号:US20060241145A1
公开(公告)日:2006-10-26
The present invention provides a piperidine derivative having antagonistic action for tachykinin receptors and the like, a crystal thereof, and an agent for the prophylaxis or treatment of diseases including lower urinary tract disease and the like, which contains the derivative. Specifically, the present invention provides an optically active compound represented by the formula (I):
wherein each symbol is as defined in the specification, and a salt thereof.
The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts,
wherein R
1a
, R
1b
, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.
[EN] C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS<br/>[FR] AMINES EN C28 DE DÉRIVÉS D'ACIDE BÉTULINIQUE MODIFIÉ EN C-3 EN TANT QU'INHIBITEURS DE MATURATION DU VIH
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2012106188A1
公开(公告)日:2012-08-09
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-28 amines of C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS. In particular, the following compounds are provided herein, including pharmaceutically acceptable salts thereof: a compound of formula (I), a compound of formula (II), and a compound of formula (III).